Personal Finance

Why Insys Therapeutics, Inc. Stock Soared 17.1% Today

Ten light-blue pills on prescription pad

What happened

Shares of Insys Therapeutics, Inc. (NASDAQ: INSY) soared 17.1% on Wednesday after the biotech announced that it had reached an agreement in principle with the U.S. Department of Justice (DOJ) to settle a civil and criminal investigation into past sales and marketing practices.

The DOJ began an investigation in late 2013 related to Insys' sales and marketing efforts for opioid drug Subsys. Insys stated that with the pending settlement agreement the company would pay $150 million over a five-year period. It may also have to make contingency-based payments "associated with certain events" that Insys' management thinks could be up to $75 million. In addition, a final settlement would likely include other nonfinancial terms and conditions.

Ten light-blue pills on prescription pad

Image source: Getty Images.

So what

The agreement in principle with the DOJ is important for Insys for a couple of key reasons. First, it could close out an ugly chapter in the biotech's history. The executives that led Insys during the period when the alleged inappropriate sales and marketing practices occurred are no longer with the company. Most of the sales team from that time are also gone.

Insys' management team has said that its top priority was to resolve the ongoing investigation and rebuild the company's reputation. With the prospects of a settlement with the DOJ now on the horizon, the biotech's executives should now be able to focus on executing the rest of their strategy.

The second reason the pending DOJ settlement is important is the price tag. Insys already set aside $150 million in the third quarter of 2017 . At the time, the company stated that it thought that would be the minimum amount required to resolve the issue. As long as the investigation continued, the fear remained that Insys might have to pay much more in a settlement. Although it could have to fork over more money in contingency-based payments, investors' fears should now be pretty much laid to rest.

Now what

Insys and the DOJ haven't signed an agreement yet, so some anxiety could remain until the ink is dry on the deal. However, it's definitely great news for the biotech to be on the verge of removing the dark cloud that has been hanging over it.

The big question now for Insys is how quickly it can return to growth. Insys' revenue continues to plunge with declining sales for Subsys and very slow sales growth for cannabinoid drug Syndros. Until the biotech can demonstrate that it has a clear pathway to growth, I think that investors are better off watching from the sidelines.

10 stocks we like better than Insys Therapeutics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Personal Finance Videos

    #TradeTalks: The Changing E-Commerce Landscape

    e-Commerce Consultant James Thomson joins Jill Malandrino on Nasdaq #TradeTalks to discuss the changing e-commerce landscape, what consumers should prepare for as we head into shopping season and why you shouldn’t do last minute shipping.

    3 days ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More